Not exact matches
Darzalex, however, has not yet reached its peak potential as the drug moves into earlier stages of the disease and is being
tested on solid tumours like
lung cancer.
The company has performed thousands of
tests and is working on detecting prostate, breast, colon, and
lung cancers.
Less than a year after growth picked up at the
test prep company, Hansoo Lee, Parikh's co-founder, passed away from
lung cancer.
Now a new clinical trial is under way, by New York's Mount Sinai, to
test a vaccine to combat recurrence in some of the most deadly forms of
cancer, including
lung, breast, gynecological and bladder
cancers.
Mount Sinai is
testing a «personalized» vaccine, aimed at combating recurrence in some of the most deadly forms of
cancer, including
lung, breast, gynecological and bladder
cancers.
The medicines, which help unleash the immune system on
cancer cells, were
tested in patients with advanced
lung cancer.
Freenome says its
tests do better than the current options for diagnosing prostate, breast, colorectal, and
lung cancers.
Mount Sinai in NY is among the first to
test a personalized vaccine for
lung, breast, gynecological and bladder
cancers.
With
lung cancer, for example, it wants to be able to resolve whether a
test shows non-small-cell
lung carcinoma or small cell
lung carcinoma.
Indeed, the 25 - person company has now
tested thousands of blood samples, and it says its
tests outperform current screening
tests on the market for four types of
cancer: prostate, breast, colorectal, and
lung.
The study has been
tested in metastatic patients with different primary tumours such as breast, colon and
lung cancer.
A team led by Lu You, an oncologist at Sichuan University's West China Hospital in Chengdu, plans to start
testing such cells in people with
lung cancer next month.
In their latest study, they
tested compounds against cells from nine different types of human
cancer, including common types affecting blood, colon, breast, prostate, ovaries, kidneys, and
lungs.
Among other
tests, they looked at tissue samples of breast
cancer that had spread to the liver,
lung and other organs.
Since the
Lung Cancer Mutation Consortium trial began in 2009, many patients are now
tested for mutated or altered genes before treatment.
«In addition to
lung cancer, we've also
tested for ovarian
cancer in this work.
The clinical trial being planned will
test the treatment in both
lung cancer patients and those with glioblastomas.
We extended our molecular diagnostics to
test for a genetic rearrangement that had been reported in lymphoma and
lung cancer, but never in mesothelioma.
HDAC inhibitors have been approved for use in blood
cancers and are being
tested for benefit in other
cancers, such as breast, colorectal, gastric, liver,
lung and prostate
cancers that overexpress specific HDAC proteins.
The company also
tested the virus in a 23 - person, early - stage trial against colorectal,
lung, ovarian and skin
cancers.
Finally, a Calgary, Alberta — based company, Oncolytics Biotech, is
testing a reovirus (an RNA virus often found in human
lungs but thought to be nonpathogenic) against several types of
cancer, including that of the
lung and skin as well as head and neck malignancies.
The five types of
cancers analyzed in this study have screening methods that allow for detection at an early stage, though in some instances, debate remains over efficacy and appropriate use: mammography for breast
cancer, colonoscopy for colorectal
cancer, Pap smear and / or HPV
test for cervical
cancer, spiral computed tomography or CT for
lung cancer, and PSA
test for prostate
cancer.
She expects she will find laminum - 8 uniquely overexpressed in other invasive
cancers, like
lung and colon
cancer, but to date she has
tested for it in only human brain and metastatic breast
cancer.
Multiplexed genetic screening for epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker - guided treatment is cost - effective compared with standard chemotherapy treatment without any molecular
testing in the metastatic non-small cell
lung cancer (NSCLC) setting in the United States.
In the first series of
tests, researchers found that luteolin inhibited the metastasis of triple - negative
cancer in the
lungs of affected mice.
To
test the notion, the scientists examined DNA from four
lung cancer patients, isolating fragments that were 20 - 50 base pairs shorter than the total average size in circulation.
To
test this idea, the researchers utilized two mouse models of human breast
cancer metastasis and found dormant disseminated tumor cells residing upon the membrane microvasculature of
lung, bone marrow and brain tissue.
«This study demonstrates the value of
testing lung cancer tissue for an ALK rearrangement, and it underscores the potential of
cancer genomics to target
cancer treatments to each patient,» says the study's senior author, Pasi A. Jänne, MD, PhD, who is the director of the Lowe Center for Thoracic Oncology of Dana - Farber.
The researchers are planning to
test this method to deliver HIV vaccines in nonhuman primates, and they are also working on further developing
cancer vaccines, including one for
lung cancer.
Right now, the
tests, which are available from several companies, mostly aid in treatment decisions for people already diagnosed with a particular form of
cancer, such as prostate or
lung.
The research, presented at the European Respiratory Society (ERS) International Congress in Munich, suggests that
testing the temperature of breath could be a simple and noninvasive method to either confirm or reject the presence of
lung cancer.
The researchers enrolled 82 people in the study who had been referred for a full diagnostic
test after an x-ray suggested the presence of
lung cancer.
In a
test designed to show how the tool would be used in actual practice, Dr. Wang retrospectively
tested iCAGES using detailed sequencing data from a patient with
lung cancer.
They also
tested other
cancer lines — human cervical,
lung and prostate
cancers — and found that they responded to the patterned tumor environments in the same way.
If we are able to refine a
test to diagnose
lung cancer by measuring breath temperature, we will improve the diagnostic process by providing patients with a stress - free and simple
test that is also cheaper and less intensive for clinicians.»
«Breath temperature
test could identify
lung cancer.»
One early project was to help Genoptix — a Novartis daughter - company acquired in 2011 and located in Carlsbad, California — to commercialize a diagnostic
test for
lung cancer patients.
Testing for the EGFR mutation and ALK rearrangements and the use of targeted therapies have given
lung cancer patients the chance for survival, along with improved quality of life and time with loved ones.
Tested on data from The
Cancer Genome Atlas (TCGA), MEGENA identified novel regulatory targets in breast and
lung cancers, outperforming other co-expression analysis methods.
In an era of precision medicine, the guideline provides recommendations for pathologists, oncologists, and other
cancer health professionals on the current state - of - the - art recommendations for the molecular
testing of
lung cancer.
«Rapid advancements in genetic
testing offer new treatment options for patients with advanced
lung cancer.
Moving forward, they plan to continue
testing derivatives of HIPP for the treatment of colon
cancer and also see if their findings extend to breast,
lung, ovarian and prostate
cancers.
In
tests on EGFR - dependent
lung cancer cell lines, Tan and colleagues show that the drugs gefitinib and bosutinib «showed additive and synergistic effects.»
«For about 80 percent of our patients with
lung cancer, we don't have
tests like [the one for] ALK to tell us what treatments will work best,» Shaw says.
The researchers are now doing clinical
testing on breast,
lung, stomach, prostate and intestinal
cancer patients» blood samples.
The group is applying advanced image analysis techniques to 4D CT scans already performed as a standard step in targeting
lung cancer radiotherapy, to map areas of
lung function without additional
testing.
«In my case, this was even more rare since I have a different version of
lung cancer than most people who were being
tested on Xalkori,» he adds.
The difference with Xalkori is that a
test exists to identify that slim percentage of
lung cancer patients (about 8,000 people in the United States and 40,000 worldwide each year) who would respond well.
Scientists from the
Cancer Research UK Manchester Institute, based at The University of Manchester and part of the Manchester Cancer Research Centre, teamed up with experts at AstraZeneca, as part of a collaboration agreed in 2010, to test a drug — known as AZD3965 — on small cell lung cancer
Cancer Research UK Manchester Institute, based at The University of Manchester and part of the Manchester
Cancer Research Centre, teamed up with experts at AstraZeneca, as part of a collaboration agreed in 2010, to test a drug — known as AZD3965 — on small cell lung cancer
Cancer Research Centre, teamed up with experts at AstraZeneca, as part of a collaboration agreed in 2010, to
test a drug — known as AZD3965 — on small cell
lung cancer cancer cells.
The Manchester researchers
tested a new drug that targets one of these molecules, MCT1, in
lung cancer cells and in mouse models.